Market News AIOpen the app

MNPR stock news · Monopar Therapeutics Inc.

Stories about Monopar Therapeutics Inc. (MNPR) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for MNPR

Follow Monopar Therapeutics Inc. (MNPR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MNPR
Free on the App Store and Google Play, or on the web.
  1. Nov 16, 2026, 5:38 PM ET · Market

    Morgan Stanley still thinks highly of Monopar Therapeutics and its drug development plans.

    Neutral

    Morgan Stanley kept its Overweight rating on Monopar Therapeutics. This repeats the firm's view without reporting a change in the company's business, so I read it as neutral.